27494870|t|Novel antibody probes for the characterization of endosialin / TEM-1
27494870|a|Endosialin (Tumor Endothelial Marker-1 (TEM-1), CD248) is primarily expressed on pericytes of tumor - associated microvasculature, tumor - associated stromal cells and directly on tumors of mesenchymal origin, including sarcoma and melanoma. While the function of endosialin/TEM-1 is incompletely understood, studies have suggested a role in supporting tumor growth and invasion thus making it an attractive therapeutic target. In an effort to further understand its role in cancer, we previously developed a humanized anti-endosialin/TEM-1 monoclonal antibody (mAb), called ontuxizumab (MORAb-004) for testing in preclinical and clinical studies. We herein report on the generation of an extensive panel of recombinant endosialin/TEM-1 protein extracellular domain (ECD) fragments and novel mAbs against ECD motifs. The domain-specific epitopes were mapped against ECD sub-domains to identify those that can detect distinct structural motifs and can be potentially formatted as probes suitable for diagnostic and functional studies. A number of mAbS were shown to cross-react with the murine and human protein, potentially allowing their use in human animal models and corresponding clinical trials. In addition, pairing of several mAbs supported their use in immunoassays that can detect soluble endosialin/TEM-1 (sEND) in the serum of healthy subjects and cancer patients.
27494870	0	5	Novel	T080	C0205314
27494870	6	14	antibody	T116,T129	C0003241
27494870	30	46	characterization	T052	C1880022
27494870	50	60	endosialin	T116,T123	C1437495
27494870	63	68	TEM-1	T116,T123	C1437495
27494870	69	123	Endosialin (Tumor Endothelial Marker-1 (TEM-1), CD248)	T116,T123	C1437495
27494870	150	159	pericytes	T025	C0598800
27494870	163	168	tumor	T191	C0027651
27494870	171	181	associated	T080	C0332281
27494870	182	198	microvasculature	T042	C0243079
27494870	200	205	tumor	T191	C0027651
27494870	208	218	associated	T080	C0332281
27494870	219	232	stromal cells	T025	C0162597
27494870	249	255	tumors	T191	C0027651
27494870	259	277	mesenchymal origin	T025	C1257975
27494870	289	296	sarcoma	T191	C1261473
27494870	301	309	melanoma	T191	C0025202
27494870	321	329	function	T169	C0542341
27494870	333	349	endosialin/TEM-1	T116,T123	C1437495
27494870	378	385	studies	T062	C2603343
27494870	422	434	tumor growth	T191	C0598934
27494870	439	447	invasion	T033	C1269955
27494870	477	488	therapeutic	T169	C0302350
27494870	489	495	target	T169	C1521840
27494870	544	550	cancer	T191	C0006826
27494870	578	587	humanized	T116,T129	C2985546
27494870	588	609	anti-endosialin/TEM-1	T116,T123	C1437495
27494870	610	629	monoclonal antibody	T116,T129	C0003250
27494870	631	634	mAb	T116,T129	C0003250
27494870	644	655	ontuxizumab	T116,T121	C2826153
27494870	657	666	MORAb-004	T116,T121	C2826153
27494870	672	679	testing	T169	C0039593
27494870	683	694	preclinical	T062	C1709631
27494870	699	715	clinical studies	T062	C0008972
27494870	741	751	generation	T052	C3146294
27494870	777	788	recombinant	T116	C0034861
27494870	789	813	endosialin/TEM-1 protein	T116,T123	C1437495
27494870	814	834	extracellular domain	T082	C1517050
27494870	836	839	ECD	T082	C1517050
27494870	841	850	fragments	T116	C0030935
27494870	855	860	novel	T080	C0205314
27494870	861	865	mAbs	T116,T129	C0003250
27494870	874	877	ECD	T082	C1517050
27494870	878	884	motifs	T087	C1514562
27494870	890	905	domain-specific	T044	C1149343
27494870	906	914	epitopes	T129	C0003316
27494870	920	926	mapped	T170	C3858752
27494870	935	938	ECD	T082	C1517050
27494870	978	984	detect	T033	C0442726
27494870	994	1004	structural	T082	C0678594
27494870	1005	1011	motifs	T087	C1514562
27494870	1068	1078	diagnostic	T062	C1704656
27494870	1083	1101	functional studies	T169	C0205245
27494870	1115	1119	mAbS	T116,T129	C0003250
27494870	1134	1145	cross-react	T059	C0541850
27494870	1155	1161	murine	T109,T121	C0591833
27494870	1166	1171	human	T016	C0086418
27494870	1172	1179	protein	T116,T123	C0033684
27494870	1215	1220	human	T016	C0086418
27494870	1221	1234	animal models	T008	C0599779
27494870	1253	1268	clinical trials	T062	C0008976
27494870	1302	1306	mAbs	T116,T129	C0003250
27494870	1330	1342	immunoassays	T059	C0523404
27494870	1359	1366	soluble	T026	C1749467
27494870	1367	1383	endosialin/TEM-1	T116,T123	C1437495
27494870	1385	1389	sEND	T116,T123	C1437495
27494870	1398	1403	serum	T031	C0229671
27494870	1407	1423	healthy subjects	T098	C1708335
27494870	1428	1443	cancer patients	T101	C1516213